drugset / Trial / NCT01776307
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer.
Timeline
- Start
- 2012-03
- Primary completion
- 2018-06
- Completion
- 2020-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Napabucasin | Small molecule | 500 mg | Oral |
| Subject | Panitumumab | Monoclonal antibody | 6 mg/kg | Intravenous |